128 related articles for article (PubMed ID: 37956490)
1. Efficacy and safety of second-line camrelizumab combined with apatinib and chemotherapy in patients with advanced lung adenocarcinoma: A prospective, open-label, multicentric study.
Yao Y; Wang Y; Du Y; Jiang F; Liang H; Bi M; Xie H; Peng W; Pan Y
Int Immunopharmacol; 2023 Dec; 125(Pt B):111147. PubMed ID: 37956490
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients.
Lv J; Zhang W; Deng R; Chen Y; Liu M; Zhang Z; Wang Q; He Y; Liu Y; Wang F; Lv Z; Zhou H; Li C; Zhang T; Fu Y; Zhao X; Bao Q; Miao Y; Wang L; Huang M; Zhang C
J Clin Pharm Ther; 2022 Aug; 47(8):1257-1263. PubMed ID: 35397125
[TBL] [Abstract][Full Text] [Related]
3. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab combined with apatinib and nanoparticle albumin-bound paclitaxel in lung adenocarcinoma (CAPAP-lung): a single-arm phase II study.
Pu X; Lin G; Xiao M; Lin J; Wang Q; Kong Y; Yan X; Xu F; Xu Y; Li J; Li K; Chen B; Wen X; Tan Y; Cheng F; Zhu K; Li N; Wu L
EClinicalMedicine; 2024 Jan; 67():102403. PubMed ID: 38261958
[TBL] [Abstract][Full Text] [Related]
5. Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Peng Z; Wei J; Wang F; Ying J; Deng Y; Gu K; Cheng Y; Yuan X; Xiao J; Tai Y; Wang L; Zou J; Zhang Y; Shen L
Clin Cancer Res; 2021 Jun; 27(11):3069-3078. PubMed ID: 33766817
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: A multi center prospective study.
Jiang Q; Zhang NL; Ma DY; Tan BX; Hu X; Fang XD
Medicine (Baltimore); 2019 Jun; 98(26):e16065. PubMed ID: 31261514
[TBL] [Abstract][Full Text] [Related]
10. Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial.
Duan JC; Wang ZJ; Lin L; Li JL; Wang Y; Bai H; Hu XS; Liu YT; Hao XZ; Wang HY; Wan R; Wang X; Wang J
Invest New Drugs; 2019 Aug; 37(4):731-737. PubMed ID: 30706337
[TBL] [Abstract][Full Text] [Related]
11. Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients.
Ma N; Qiao H; Tao H; Gan X; Shan Z; Chen X; Zhou X
Clin Res Hepatol Gastroenterol; 2022; 46(7):101962. PubMed ID: 35636681
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of camrelizumab plus apatinib as second-line treatment for advanced squamous non-small cell lung cancer.
Gao G; Zhao J; Ren S; Wang Y; Chen G; Chen J; Gu K; Guo R; Pan Y; Wang Q; Li W; Yang X; Zhou C
Ann Transl Med; 2022 Apr; 10(8):441. PubMed ID: 35571422
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of camrelizumab plus apatinib compared to apatinib monotherapy as third-line or above therapy for metastatic colorectal cancer patients: A retrospective cohort study.
Li C; Yu F; Xu W
J Clin Pharm Ther; 2022 Dec; 47(12):2325-2334. PubMed ID: 36495117
[TBL] [Abstract][Full Text] [Related]
14. Apatinib plus Chemotherapy as a Second-Line Treatment in Unresectable Non-Small Cell Lung Carcinoma: A Randomized, Controlled, Multicenter Clinical Trial.
Yu Z; Cai X; Xu Z; He Z; Lai J; Wang W; Zhang J; Kong W; Huang X; Chen Y; Shi Y; Shi X; Zhao Z; Ni M; Lin X; Chen S; Wu X; Chen W; Song Z; Huang C
Oncologist; 2020 Nov; 25(11):e1640-e1649. PubMed ID: 32533785
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of camrelizumab combined with albumin-bound paclitaxel as third- or later-line regimen in patients with advanced non-small cell lung cancer.
Zhu J; Yu Y; Mei J; Chen S; Li J; Jiang S
Front Immunol; 2023; 14():1278573. PubMed ID: 38124737
[TBL] [Abstract][Full Text] [Related]
16. The addition of camrelizumab is effective and safe among unresectable hepatocellular carcinoma patients who progress after drug-eluting bead transarterial chemoembolization plus apatinib therapy.
Wang M; Sun L; Han X; Ren J; Li H; Wang W; Xu W; Liang C; Duan X
Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102060. PubMed ID: 36473631
[TBL] [Abstract][Full Text] [Related]
17. A combination of anti-PD-1 therapy and apatinib successfully treated a patient with EGFR mutation-negative advanced lung adenocarcinoma: A case report.
Wang J; Li S; Zhang L; Zhang X
J Cancer Res Ther; 2023 Feb; 19(1):141-143. PubMed ID: 37006054
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab combined with apatinib for unresectable, metastatic esophageal squamous cell carcinoma: a single-center, single-arm, prospective study.
Qu Y; Munire A; Zhou N; Saifuding K; Bulibu J; Wang W; Tang X; Li N; Li J; Wang P; Tang Y
J Gastrointest Oncol; 2024 Feb; 15(1):1-11. PubMed ID: 38482217
[TBL] [Abstract][Full Text] [Related]
19. [Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].
Yuan GS; He WM; Hu XY; Li Q; Zang MY; Cheng X; Huang W; Ruan J; Wang JJ; Hou JL; Chen JZ
Zhonghua Gan Zang Bing Za Zhi; 2021 Apr; 29(4):326-331. PubMed ID: 33979958
[No Abstract] [Full Text] [Related]
20. Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study.
Li X; Zhang Q; Lu Q; Cheng Z; Liu F; Han Z; Yu X; Yu J; Liang P
Front Immunol; 2022; 13():1023983. PubMed ID: 36389778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
